From: Recent advances of PET imaging in clinical radiation oncology
Tumor entity | Tracers | Indication | Comment |
---|---|---|---|
Glioma | 18F-FET | TD/P/TR | Valuable as longer halftime compared to 11C-MET, high diagnostic accuracy with histopathological validation; ongoing trials to confirm clinical benefit, e. g. GLIAA [25] |
18F-DOPA | TD/P/TR | Studies on prognostic relevance and histopathological validation available, e.g. [24, 26], mainly used in the US | |
11C-MET | TD/P | Studies on prognostic relevance and histopathological validation available. Aiding in target delineation. | |
TSPO ligands | None | Investigational, no histopathological validation studies (ongoing) | |
Meningioma | 68Ga-DOTATOC | TD | Aiding in target delineation or surgical approach, especially when located at the skull base |
68Ga-DOTATATE | TD | SUV cutoff histologically validated, no relevant data available on response | |
Brain metastasis | 18F-FET | TR | Differentiation pseudoprogression/radiation necrosis vs. tumor recurrence |
CNS lymphoma | 18F-FDG | None | Tumor metabolism, response assessment [27] |